Apimeds Pharmaceuticals US, Inc. (APUS)
| Market Cap | 18.75M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -1.50M |
| Shares Out | 11.58M |
| EPS (ttm) | -0.19 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 32,626 |
| Open | 1.620 |
| Previous Close | 1.610 |
| Day's Range | 1.602 - 1.694 |
| 52-Week Range | 1.370 - 4.000 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 22, 2025 |
About APUS
Apimeds Pharmaceuticals US, Inc. operates as a clinical stage biopharmaceutical company in the United States. It researches, develops, manufactures, commercializes, and sells Apitox, a purified, pharmaceutical grade venom of the Apis mellifera, or honeybee for the treatment of inflammation and pain management symptoms associated with osteoarthritis and multiple sclerosis. The company was incorporated in 2020 and is based in Matawan, New Jersey. [Read more]
News
Apimeds Expands Leadership Team with Dr. Susan Kramer to Lead Product Development and Brian Peters to Lead its ai² Division
MATAWAN, N.J.--(BUSINESS WIRE)--Apimeds Pharmaceuticals US, Inc. (NYSE American: APUS) (“Apimeds” or the “Company”), a clinical-stage biopharmaceutical company developing Apitox, an intradermally admi...
Apimeds Pharmaceuticals US, Inc. Announces Closing of Initial Public Offering
Hopewell, New Jersey, May 12, 2025 (GLOBE NEWSWIRE) -- Apimeds Pharmaceuticals US, Inc. (NYSE American: APUS) (“Apimeds” or the “Company”), a clinical stage biopharmaceutical company that is in the pr...
U.S. IPO Weekly Recap: Sizable Insurance IPOs Deliver Solid Trading
A few new issuers went public this past week, joined by two SPACs. Three IPOs are scheduled to list in the week ahead, although some small deals may join the calendar at the last minute. Street resear...
Apimeds Pharmaceuticals US, Inc. Announces Pricing of Initial Public Offering
Hopewell, New Jersey, May 08, 2025 (GLOBE NEWSWIRE) -- Apimeds Pharmaceuticals US, Inc. (NYSE American: APUS) (“Apimeds” or the “Company”), a clinical stage biopharmaceutical company that is in the pr...
Inflammation-focused biotech Apimeds Pharmaceuticals US files for a $12 million IPO
Apimeds Pharmaceuticals US, a clinical stage biotech developing a bee venom-based treatment for inflammation, filed on Wednesday with the SEC to raise up to $12 million in an initial public offering.
Apimeds Pharmaceuticals US IPO Registration Document (S-1)
Apimeds Pharmaceuticals US has filed to go public with an IPO on the NYSE American